Most argumentation identified in our study indicated different perspectives on the efficacy (glucose-lowering potential), safety (hypoglycemia, body weight) and applicability (flexibility in injection time and site, applicability of device) of the insulins to patients. The gene discussed is INS; the disease is Hypoglycemia.